{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:35:49Z","timestamp":1793748949367,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115365","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:40:00Z","timestamp":1743655200000},"page":"115365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-6966","authenticated-orcid":false,"given":"Robert C.","family":"Stassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8001-1311","authenticated-orcid":false,"given":"Antonius W.","family":"Schurink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-1907","authenticated-orcid":false,"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-6791","authenticated-orcid":false,"given":"Loes M.","family":"Hollestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115365_bib1","unstructured":"ECIS. Estimates of cancer incidence and mortaility in 2022, for all countries: European Commission; 2024 [Available from: \u3008https:\/\/ecis.jrc.ec.europa.eu\/explorer.php?$0-0$1-All$2-All$4-1,2$3-27$6-0,85$5-2022,2022$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27\u3009."},{"issue":"19","key":"10.1016\/j.ejca.2025.115365_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2025.115365_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2025.115365_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115365_bib5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2014Melanoma: Cutaneous (Version 2.2024), April 3, 2024: National Comprehensive Cancer Network; [Available from: \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf\u3009."},{"issue":"6","key":"10.1016\/j.ejca.2025.115365_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/bjd\/ljad244","article-title":"Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden","volume":"189","author":"Vikstr\u00f6m","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115365_bib7","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1245\/s10434-022-11761-4","article-title":"Evaluation of the indications for sentinel node biopsy in early-stage melanoma with the advent of adjuvant systemic therapy: an international, multicenter study","volume":"29","author":"Moncrieff","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115365_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107249","article-title":"Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study","volume":"49","author":"Stassen","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115365_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American joint committee on cancer (AJCC) and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115365_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115365_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2025.115365_bib12","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2025.115365_bib13","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","article-title":"Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma","volume":"31","author":"Han","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115365_bib14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.6004\/jnccn.2009.0023","article-title":"Role of sentinel lymph node biopsy in patients with thin melanoma","volume":"7","author":"Andtbacka","year":"2009","journal-title":"J Natl Compr Cancer Netw"},{"issue":"27","key":"10.1016\/j.ejca.2025.115365_bib15","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.20.01460","article-title":"Reply to E. Hindi\u00e9","volume":"38","author":"Maurichi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115365_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-020-00810-3","article-title":"The importance of prognostication: impact of prognostic predictions, disclosures, awareness, and acceptance on patient outcomes","volume":"22","author":"Hui","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115365_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","article-title":"Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis","volume":"25","author":"Stassen","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115365_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115365_bib19","first-page":"835","article-title":"Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial","volume":"157","author":"Crystal","year":"2022","journal-title":"JAMA Surg"},{"issue":"24","key":"10.1016\/j.ejca.2025.115365_bib20","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.19.02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram","volume":"38","author":"Lo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115365_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1245\/ASO.2005.05.016","article-title":"A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system","volume":"12","author":"Wong","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115365_bib22","doi-asserted-by":"crossref","unstructured":"Gershenwald J.E., Thompson W., Mansfield P.F., Lee J.E., Colome M.I., Tseng C.H. Multi-institutional melanoma lymphatic mapping experience. the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. 1999;1999:17.","DOI":"10.1200\/JCO.1999.17.3.976"},{"issue":"3","key":"10.1016\/j.ejca.2025.115365_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0b013e3181855718","article-title":"Regional recurrence after negative sentinel lymph node biopsy for melanoma","volume":"248","author":"Carlson","year":"2008","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ejca.2025.115365_bib24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25\u00a0720 Patients With Stage IA to IV Melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115365_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2133.2002.04867.x","article-title":"Metastatic pathways and time courses in the orderly progression of cutaneous melanoma","volume":"147","author":"Meier","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2025.115365_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115365_bib27","unstructured":"Cancercentrum. Nationellt v\u00e5rdprogram melanom: Regionala Cancercentrum; 2024 [Available from: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/melanom\/vardprogram\/."},{"issue":"4","key":"10.1016\/j.ejca.2025.115365_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jso.25208","article-title":"Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts","volume":"118","author":"Isaksson","year":"2018","journal-title":"J Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115365_bib29","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.ejca.2025.115365_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"34","key":"10.1016\/j.ejca.2025.115365_bib31","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.21.02488","article-title":"Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer IIIA Disease","volume":"40","author":"Moncrieff","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:49:46Z","timestamp":1760640586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S0959804925001467"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115365","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115365"}}